15p next week |
what the divi 4.4% ? |
gsk definitely on the naughty step at the moment. Xd next week. |
I was anticipating a trump victory and while not too unhappy at the thought of the rally in shares in the aftermath was not expecting the markets to take such a dim view here and in europe .
Looks like I jumped in too soon with this one from what I am reading on the internet and comments passed.
I had put it all down to Astra Zenecas tribulations but it seems as if the infection and fear has spread.
Just have to tough it out until things become clearer and I can get some direction, In the meantime the dividend pours some salve on the wound but I will have to suffer the pain for some time to come.
Be good and be lucky |
Can watch the clip yourself. I’d expect more legal issues and similar cases to Zantac if RFK gets the gig.
hxxps://youtu.be/vfLZOkn0chc?si=_7RBCZG-mN83hD_- |
TM
You do realise all of that was disingenuous bollux right. Peddled by a biased left wing MSM..
It's been a great day
A whitewash
A red wave.
Very satisfying. |
At this rate I'd expect some buying for the dividend next week - xd 14 Nov (15p/share) |
I think his main remit and focus reading is on chemicals in food and not drugs for medical conditions |
Still blue on the day though. Healthcare -1.25% |
FTSE has dropped 70pts from this morning. |
This drop is specifically pharma / healthcare related. Trump will give a major role to Bobby Kennedy and he's a well known critic of vaccine safety |
Most of UK falling now, so normal service resumed on the UK mkt after an exciting 3 hour break |
GSK & AZN both falling now. |
China already bashed GSK some years ago so hopefully not in their crosshairs again! |
AZN? No linkage there! |
"Early data release on weight loss drug portfolio disappoints"
AstraZeneca fell 8.2%, losing its top spot as the most valuable company on the FTSE 100 to oil major Shell in the process.
The Cambridge-based pharmaceuticals firm fell back following the release of early data on its weight loss drug portfolio.AstraZeneca had revealed early data for its prospective weight loss drug at the ObesityWeek 2024 meeting in San Antonio, Texas on Monday.
Deutsche Bank reiterated a 'sell' rating following the update, noting the GLP-1 data "was somewhat underwhelming".
Jefferies took a less pessimistic view noting the data was "largely incremental, as expected."
After the closing bell, AstraZeneca noted its share price movement. It said it is not commenting on "speculative media reports including those related to ongoing investigations in China".
"If requested, we will fully cooperate with the Chinese authorities," Astra said. |
It's fairly old News that though |
It may be that AZN is down on this:
Report finds China targeted AstraZeneca in fraud probe over cancer treatment
The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, report says |
Think it might be down on back of yet another court action but this time against Astra-Zeneca and the covid jab
I will suffer the consequences as will we all |
It is today at these prices. Money being pulled from UK funds as per usual |
Not sure why GSK is down ANOTHER 1.5% today - this used to be a quality company to own ?! |
PEAT
Just got given a few more at 1402
Now I am happy
Hope this satisfies your mendacious misguided comments
Regards
Jibby |
I would prefer it to be a £90 billion company.. :) |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
